Genelux (GNLX) Accumulated Expenses (2022 - 2026)

Genelux's (GNLX) quarterly Accumulated Expenses came in at $861000.0 in Q1 2026, down 40.21% quarter-over-quarter from $1.4 million in Q4 2025.

Genelux (GNLX) Accumulated Expenses (2022 - 2026) Analysis & Trends

Genelux's Accumulated Expenses history runs 5 years deep, the most recent figure standing at $861000.0 for Q1 2026.

  • On a quarterly basis, Accumulated Expenses changed N/A year-over-year to $861000.0 in Q1 2026; TTM through Mar 2026 was $861000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $1.4 million, down 78.1% from the prior year.
  • Accumulated Expenses fell to $861000.0 in Q1 2026 per GNLX's latest filing, from $1.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $6.6 million in Q4 2024 and bottomed at $11000.0 in Q3 2023.
  • The 5-year median for Accumulated Expenses is $861000.0 (2026), against an average of $1.5 million.
  • Across the five-year window, Accumulated Expenses soared 6136.36% in 2024 and tumbled 78.1% in 2025, its largest moves.
  • Year by year, Accumulated Expenses stood at $1.2 million in 2022, then jumped by 79.71% to $2.1 million in 2023, then jumped by 210.53% to $6.6 million in 2024, then tumbled by 78.1% to $1.4 million in 2025, then tumbled by 40.21% to $861000.0 in 2026.
  • Per Business Quant, the three latest GNLX Accumulated Expenses figures stand at $861000.0 (Q1 2026), $1.4 million (Q4 2025), and $800000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Genelux 129.36 Mn 129.36 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 861,000.00
Dec 31, 2025 1.44 Mn
Sep 30, 2025 800,000.00
Jun 30, 2025 610,000.00
Dec 31, 2024 6.57 Mn
Sep 30, 2024 686,000.00
Jun 30, 2024 517,000.00
Mar 31, 2024 1.91 Mn
Dec 31, 2023 2.12 Mn
Sep 30, 2023 11,000.00
Dec 31, 2022 1.18 Mn